MEDICAMEN Biotech Limited



Date: 18.11.2025

Regd. & Corp. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi - 110019 (INDIA) Tel.: 011 - 47589500-51 (50 Lines), E-mail: info@medicamen.com Web: www.medicamen.com CIN No.: L74899DL1993PLC056594

Ref: STEX/Results/Published-2025-26

To

BSE Limited Floor 25, P J Towers Dalal Street Mumbai-400001 National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051

BSE Code-531146

NSE Code: MEDICAMEQ

Sub.: Copy of Publication for Un-audited Financial Results for the quarter and half year ended on September 30, 2025

Dear Sir,

Pursuant to regulation 30 & 47 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015 ("the Regulations"), please find enclosed newspaper cutting with regard to the publication of extract of Un-audited Financial Results of the Company for the quarter and half year ended on September 30, 2025 approved by the Board of Directors at their Meeting held on 14.11.2025.

The copy of the results published in the Financial Express and Jansatta dated 15.11.2025 is enclosed.

This is for your information and records.

Kindly acknowledge the receipt.


Thanking You,

Yours truly,

For Medicamen Biotech Limited

Parul Choudhary Company Secretary ACS-44157

Encl: As above.



Modern Engine

103/4 Plot -215, Free Press House, FI-10, Free Pre E-mail: cs@mep.ltd; Website: www.r

STATEMENT OF UNAUDITED FINANCIAL YEAR ENDED SE

T		C		
Sr. No.	Paticulars	Sep 30, 2025		
140.		Unaudited		
1	Total income from operations	1,790.34		
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/ or Extraordinary items)	436.70		
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items).			
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	293.75		
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	295.22		
6	Equity Share Capital	1,545.0		
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year			
8	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) -			
	1. Basic	1.9		
	2. Diluted	1.9		

MEDICAMEN BIOTECH LIMITED

Reg. Office: 1506, Chiranjiv Tower, 43, Nehru Place,

New Delhi, 110019 (India)

CIN: L74899DL1993PLC056594 Contact No.: 011-47589500 Website: www.medicamen.com Email: info@medicamen.com

Statement of Un-audited Financial Results (Standalone and Consolidated) for the quarter and half year ended on September 30, 2025

Based on the recommendation of Audit Committee, the Board of Directors of the Company, at their meeting held on November 14, 2025, approved the Un-audited financial results (Standalone & Consolidated) of the Company for the quarter and half year ended on September 30, 2025.

The financial results along with Limited Review Report have been posted on the website of the Company at www.medicamen.com and can be accessed by scanning the QR code given below:



For and on behalf of Board of **Directors of Medicamen Biotech Limited**

> Sd/-Rahul Bishnoi

Director

Year Ended 31.03.2025

(Audited)

10,796.54

1.966.92

DIN: 00317960

RUDRABHISHEK ENTERPRISES LIMITED

Regd. Office: 820, ANTRIKSHA BHAWAN, K.G.MARG NEW DELHI DL 110001 IN

CIN: L74899DL1992PLC050142

Website: www.repl.global, Email: secretarial@replurbanplanners.com

*Not annualised The above financial result is filed with the stock exclunaudited Standalone and Consolidated Financial Results for the Quarter & Half Year ended 30th September, 2025 in lacs (Except Earning per Share)

Place: New Delhi

Date: 14.11.2025

Disclosure Requirements), Regulations 2015. The deta

of Stock Exchange viz. www.bseindia.com the same is

Place: Mumbai Date: November 13, 2025

	Standalone						Consolidated						
7 1 . Th	Quarter Ended			CACA COMPANION - THE COMPANION		Year Ended	Quarter Ended			Half. Year Ended			
	30.09.2025 (Unaudited)	30.09.2024 (Unaudited)	30.06.2025 (Unaudited)	30.09.2025	30.09.2024 (Unaudited)	31.03.2025 (Audited)	30.09.2025 (Unaudited)	30.09.2024 (Unaudited)	30.06.2025 (Unaudited)	30.09.2025 (Unaudited)	30.09.2024 (Unaudited)		
	1,860.01	1,819.81	1,757.77	3,617.78	3,624.84 955.51	9,700.51 1,929.84	2,159.03 178.76	2,024.31 519.75	1,973.40 321.43	4,132.43 500.19	The Allendaria	1	
od	208.02	386.95	247.63	455.64	638.58	1,329.56	94.60	393.75	248.52	343.12	657.35	The second second	

657.35 1,353.08 (CIN: L291e period (after tax) 1,359.61 657.18 355.68 386.43 249.76 1,324.13 105.93 463.98 626.97 Regd. Office: Block No.35/1-2-3-4, Villagne (after tax)] 247.78 216.21 379.51 1.812.25 1.734.25 1,812.25 1.812.25 1.734.25 1.812.25 1.812.25 1.734.25 Tel No: +91-2716-247236, +91-2716-269399, Fax No.: +91-2711 1.812.25 1.812.25 1.734.25 1.812.25 EXTRACT OF THE UNAUDITED FINANCIAL RESULTS ed) 3.79 7.69 1.89 1.37 2.27 0.52 3.68 1.37 2.23 1.15 3 63 7.69

राजमार्ग इंफ्रा इन्वेस्टमेंट मैनेजर्स प्राइवेट लिमिटेड

पंजीकृत कार्यालय: G-5 & 6, सेक्टर-10, द्वारका, दिल्ली — 110075 CIN: U66309DL2025PTC453624 ईमेल: info.riimpl@nhai.org; दूरभाष: 011-25074100

भर्ती सूचना

दिनांक: 15-11-2025

RIIMPL निम्नलिखित पदों के लिए अनुबंध के आधार पर आवेदन आमंत्रित करता है:

- a) उपाध्यक्ष (प्रशासन एवं संचालन) 01 पद
- b) प्रबंधक (वित्त) 01 पद
- c) कंपनी सचिव 01 पद

विस्तृत विज्ञापन RIIMPL की वेबसाइट (https://www.riimpl.in/) पर उपलब्ध है। आवेदन की अंतिम तिथि 30/11/2025 (शाम 6 बजे तक) है।

अांचलिक कार्यालय, 55, द मॉल, मेरठ केंट, मेरठ– 250001

(अवन संपतियों के विक्रय हेतु विक्रय नोटिस)
दिनांक 08.11.2025 को जनसत्ता (दिल्ली संस्करण) में
सरफेसी एक्ट के तहत ई—नीलामी विक्रय नोटिस अचल
सम्पत्ति हेतु प्रकाशित की गई है। क्र0संठ 1, शाखाः पिन्ना,
ऋणीः जएमएस बिल्ड एस्टेट की होने वाली ई—नीलामी
दिनांक 26.11.2025 को रह की जा रही हैं। ई—नीलामी की

दिनांकः 14.11.2025 स्थानः मेरठ

अन्य सभी नियम व शर्ते पुवर्वत रहेंगी।

प्राधिकृत अधिकारी, इंडियन बैंक

MEDICAMEN BIOTECH LIMITED

Reg. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi, 110019 (India)

CIN: L74899DL1993PLC056594 Contact No.: 011-47589500 Website: www.medicamen.com Email: info@medicamen.com



Statement of Un-audited Financial Results (Standalone and Consolidated) for the quarter and half year ended on September 30, 2025

Based on the recommendation of Audit Committee, the Board of Directors of the Company, at their meeting held on November 14, 2025, approved the Un-audited financial results (Standalone & Consolidated) of the Company for the quarter and half year ended on September 30, 2025.

The financial results along with Limited Review Report have been posted on the website of the Company at www.medicamen.com and can be accessed by scanning the QR code given below:



For and on behalf of Board of Directors of Medicamen Biotech Limited

Sd/-

Rahul Bishnoi

Director

DIN: 00317960

Place: New Delhi Date: 14.11.2025